#Cosibelimab is anti-PD-L1 therapy for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. In contrast to anti-PD-L1 antibodies, cosibelimab can induce antibody-dependent cell mediated cytotoxicity as it incl a functional Fc domain
April 27, 2025 at 4:15 AM
#Cosibelimab is anti-PD-L1 therapy for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. In contrast to anti-PD-L1 antibodies, cosibelimab can induce antibody-dependent cell mediated cytotoxicity as it incl a functional Fc domain
#oncology #generics #SunPharma #Unloxcyt #cosibelimab #CSCC #squamouscellcarcinoma #mCSCC #SCC #laCSCC #FDA #CK301101 #clinicaltrial #skincancer #headandneckcancer #checkpointinhibition #checkpointinhibitor
pharmatimes.com/news/sun-pha...
pharmatimes.com/news/sun-pha...
Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma - PharmaTimes
More than 71% of patients treated with Unloxcyt achieved disease control
pharmatimes.com
January 28, 2026 at 12:41 PM
Nimotuzumab plus image-guided radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: Interim analysis of a prospective multi-center phase Ⅱ trial. www.redjournal.org/article/S036...
Nimotuzumab plus image-guided radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: Interim analysis of a prospective multi-center phase Ⅱ trial
Elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC) generally
have fewer therapeutic choices. Nimotuzumab, as an epidermal growth factor receptor
(EGFR)-targeted humanized...
www.redjournal.org
November 6, 2025 at 12:45 PM
Nimotuzumab plus image-guided radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: Interim analysis of a prospective multi-center phase Ⅱ trial. www.redjournal.org/article/S036...